Preparation of β-Cyclodextrin Conjugated, Gelatin Stabilized SBA 15-CuInS2/ZnS Quantum Dot Nanocomposites for Camptothecin Release

Abstract

Camptothecin (CPT) is a potential anticancer drug. However, it faces challenges due to its poor water solubility and the need for an efficient drug release system. Herein, we developed a novel system composed of gelatin stabilized, mesoporous silica SBA15 encapsulated CuInS2/ZnS (CIS/ZnS) quantum dots (QDs) conjugated with β-cyclodextrin (β-CDs) for its potential use in the release of CPT. In this multifunctional system, β-CDs served as the drug carrier, SBA15 encapsulated QDs is capable of imaging and the gelatin was used to enhance the carrier-drug interaction. Fourier transform infrared (FTIR) analysis confirmed the successful conjugation of β-CDs to the Gel-SBA15 CIS/ZnS QDs, while optical analyses revealed excellent emission properties and high photostability. The β-CD-conjugated Gel-SBA15-CIS/ZnS QD nanocomposite was used to obtain the soluble derivate of CPT which further demonstrated a drug release profile following the triphasic model. Overall, the improved photostability and acceptable drug release profile of the β-CD conjugated Gel-SBA15-CIS/ZnS QD nanocomposite hold great promise for both imaging and therapeutic applications.Graphical